Patents Assigned to The United States of America,as represented by the Secretary, Department of Health and Human Servic
-
Publication number: 20200181618Abstract: RNA aptamers are disclosed with distinct fluorescent properties, fluorophore binding affinities, and salt dependence. Also disclosed are corresponding fluorophores, with selected fluorophores evidencing high cellular permeability. The aptamer's high fluorophore affinities, the high brightness of the bound complexes, and their thermal and salt stability, provide distinct aspects of the disclosed aptamers.Type: ApplicationFiled: April 23, 2018Publication date: June 11, 2020Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE STRASBOURG, SIMON FRASER UNIVERSITY, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICInventors: Michael Ryckelynck, Alexis Autour, Peter Unrau, Elena Dolgosheina, Sunny Chiu Yuk Jeng, Shanker Shyam Sundhar Panchapakesan, Amir Abdolahzadeh, Razvan Cojocaru, Adrian Ferré D'Amaré, Robert Trachman
-
Publication number: 20200179536Abstract: Conformationally restricted cyanine fluorophores, as well as methods of making and using the compounds, are described. The conformationally restricted cyanine fluorophores have a chemical structure according to Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof: wherein A is and wherein each “*” designates an attachment point of A.Type: ApplicationFiled: August 24, 2018Publication date: June 11, 2020Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Martin J. Schnermann, Megan S. Michie
-
Publication number: 20200178964Abstract: A surgical clamp for aligning the margins of incised or wounded tissue has jaws with parallel clamping faces, and a handle for manipulating the clamp to align the margins of the tissue. The jaws are in a normally closed position, however they can be opened by compressing the handle to open the jaws. Prongs project from the inferior surface of the jaws. The clamp is positioned in a desired position over the margins of a wound to be closed, the prongs engage the margins of the wound to be aligned, and the jaws are closed by releasing compressive force on the handle. As the jaws close the prongs help move the tissue into alignment. Suture guide slots through the jaws assist in the placement of precisely placed sutures across the incision. The disclosed surgical clamp is particularly suited for selectively closing and reopening surgical incisions, such as a sclerotomy incision in the eye. Methods are disclosed for using the clamp during intraocular and other surgical or minimally invasive procedures.Type: ApplicationFiled: November 8, 2017Publication date: June 11, 2020Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICInventors: Vladimir R. Khristov, Steven T. Charles, Juan A. Amaral, Arvydas Maminishkis, Kapil Bharti
-
Publication number: 20200140915Abstract: The present disclosure provides a biosignature that distinguishes Lyme disease, including early Lyme disease, from STARI. The present disclosure also provides methods for detecting Lyme disease and STARI, as well as methods for treating subjects diagnosed with Lyme disease or STARI.Type: ApplicationFiled: December 4, 2019Publication date: May 7, 2020Applicants: Colorado State University Research Foundation, The United States of America, as represented by the secretary, Department of Health and Human ServicInventors: John T. Belisle, Claudia R. Molins, Gary P. Wormser
-
Publication number: 20200121782Abstract: Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic and retains a substantially intact rotavirus particle structure. Vaccine compositions and methods of vaccinating a subject against rotavirus are provided which include generation and use of thermally inactivated rotavirus.Type: ApplicationFiled: December 20, 2019Publication date: April 23, 2020Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Baoming Jiang, Roger I. Glass, Jean-Francois Saluzzo
-
Publication number: 20200121781Abstract: Attenuated G9P[6] rotavirus is disclosed herein. In some embodiments, pharmaceutical compositions are disclosed that include an attenuated G9P[6] rotavirus, or a component thereof. These compositions can be used to induce an immune response, such as a protective immune response, to a rotavirus. The compositions can be used as vaccines, such as for children (infants), for example in a prime boost strategy.Type: ApplicationFiled: December 17, 2019Publication date: April 23, 2020Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICInventors: Baoming Jiang, Yuhuan Wang
-
Publication number: 20200101086Abstract: Embodiments of a method for inhibiting viral infection in a subject are provided herein. In some embodiments, the method comprises administration of a competitive antagonist of ouabain binding to ATP1A1 to inhibit respiratory syncytial virus infection in the subject.Type: ApplicationFiled: September 26, 2019Publication date: April 2, 2020Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Peter Collins, Matthias Lingemann, Shirin Munir
-
Publication number: 20200101072Abstract: Disclosed is the use of a nucleoside reverse transcriptase inhibitor, a nucleotide reverse transcriptase inhibitor, and an integrase inhibitor after exposure to a potential human immunodeficiency virus (HIV) infection to inhibit or prevent an HIV infection. In some embodiments, a pharmacologically effective amount of emtricitabine (FTC), a pharmacologically effective amount of tenofovir alafenamide (TAF) or tenofovir disproxil fumarate (TDF), a pharmacologically effective amount of the integrase inhibitor elvitegravir (EVG), and optionally cobistat (COBI) are used to inhibit or prevent an HIV infection, wherein these agents are administered only after a potential exposure to HIV. In specific non-limiting examples, only one or two doses of the anti-retroviral viral agents are administered to a subject after the potential exposure to HIV.Type: ApplicationFiled: March 19, 2018Publication date: April 2, 2020Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICInventors: Jose Gerardo Garcia Lerma, Ivana Mabel Massud, Walid M. Heneine
-
Publication number: 20200095637Abstract: High efficiency methods for producing retinal pigment epithelial cells from induced pluripotent stem cells (iPSCs) are disclosed herein. The iPSCs are produced from somatic cells, including retinal pigment epithelial (RPE) cells, such as fetal RPE stem cells. In some embodiments, the iPSC include a tyrosinase promoter operably linked to a marker. Methods are disclosed for using the RPE cells, such as for treatment. Methods for screening for agents that affect RPE differentiation are also disclosed.Type: ApplicationFiled: September 27, 2019Publication date: March 26, 2020Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicInventors: Kapil Bharti, Janine Davis
-
Publication number: 20200085950Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: ApplicationFiled: November 25, 2019Publication date: March 19, 2020Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Hisataka Kobayashi, Peter Choyke
-
Publication number: 20200061185Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.Type: ApplicationFiled: October 25, 2017Publication date: February 27, 2020Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Scripps Research Institute, Trustees of Dartmouth CollegeInventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
-
Publication number: 20200054741Abstract: The present disclosure relates to novel peptide-based vaccines, methods of manufacturing the novel peptide-based vaccines and uses thereof for delivering peptide antigens to induce an immune response, and in particular a T cell response to a subject.Type: ApplicationFiled: April 4, 2018Publication date: February 20, 2020Applicants: Avidea Technologies, Inc., The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Geoffrey Martin Lynn, Andrew Scott Ishizuka
-
Publication number: 20200046747Abstract: Methods are disclosed for treating a subject with a vascular or cardiac disorder associated with oxidative stress. Methods are disclosed for treating a subject with GNE myopathy that has impaired cardiac function. These methods include administering to the subject a therapeutically effective amount of a sialic acid precursor, sialic acid, or one or more sialylated compounds, mannosamine, N-acetyl mannosamine or a derivative thereof. In other embodiments, methods are disclosed for detecting a disorder associated with oxidative stress.Type: ApplicationFiled: October 16, 2019Publication date: February 13, 2020Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Marjan Huizing, May C. Malicdan, Nuria Carrillo
-
Publication number: 20200038388Abstract: The present invention provides a method of inhibiting release of a virus from a cell, comprising contacting the cell with a compound that binds an ubiquitin E2 variant (UEV) domain of a cellular polypeptide, or fragment thereof, with an affinity sufficient to inhibit or disrupt the binding of the cellular polypeptide, or fragment thereof, to ubiquitin.Type: ApplicationFiled: October 30, 2017Publication date: February 6, 2020Applicants: The Research Foundation for the State University of New York, THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicInventors: Carol Carter, Lorna Erlich, Nico Tjandra, Madeleine Davison
-
Publication number: 20200030261Abstract: This disclosure concerns the discovery of the use of fenoterol analogues for regulating cannabinoid (CB) receptor activity-related disorders and disease, such as dysregulated CB receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular carcinoma, liver cancer, colon cancer, and/or lung cancer, which is associated with altered cannabinoid receptor activity. In one example, the method includes administering to a subject having or at risk of developing a disorder or disease regulated by CB receptor activity an effective amount of a fenoterol analogue to reduce one or more symptoms associated with the disorder or disease regulated by CB receptor activity.Type: ApplicationFiled: October 11, 2019Publication date: January 30, 2020Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Irving W. Wainer, Michel Bernier, Rajib K. Paul
-
Publication number: 20200009243Abstract: Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.Type: ApplicationFiled: September 23, 2019Publication date: January 9, 2020Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, Institute for Research in BiomedicineInventors: Peter Kwong, Michael Gordon Joyce, Baoshan Zhang, Yongping Yang, Peter Collins, Ursula Buchholz, Davide Corti, Antonio Lanzavecchia, Guillaume Stewart-Jones
-
Publication number: 20190374561Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.Type: ApplicationFiled: May 20, 2019Publication date: December 12, 2019Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicInventors: Marjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk
-
Publication number: 20190370965Abstract: Disclosed prostate computer aided diagnosis (CAD) systems employ a Random Forest classifier to detect prostate cancer. System classify individual pixels inside the prostate as potential sites of cancer using a combination of spatial, intensity and texture features extracted from three sequences. The Random Forest training considers instance-level weighting for equal treatment of small and large cancerous lesions and small and large prostate backgrounds. Two other approaches are based on an AutoContext pipeline intended to make better use of sequence-specific patterns. Also disclosed are methods and systems for accurate automatic segmentation of the prostate in MRI. Methods can include both patch-based and holistic (image-to-image) deep learning methods for segmentation of the prostate. A patch-based convolutional network aims to refine the prostate contour given an initialization. A method for end- to-end prostate segmentation integrates holistically nested edge detection with fully convolutional networks.Type: ApplicationFiled: February 22, 2018Publication date: December 5, 2019Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Nathan S. Lay, Yohannes Tsehay, Ronald M. Summers, Baris Turkbey, Matthew Greer, Ruida Cheng, Holger Roth, Matthew J. McAuliffe, Sonia Gaur, Francesca Mertan, Peter Choyke
-
Publication number: 20190314459Abstract: The present invention refers to a GPR101 inhibitor, antagonist or inverse agonist or inverse agonist for use in preventive and/or therapeutic treatment of diseases selected from the group consisting of acromegaly and gigantism and to methods for preventive and/or therapeutic treatment of diseases selected from the group consisting of acromegaly and gigantism. Further, the present invention provides a GPR101 agonist for use in preventive and/or therapeutic treatment of disorders selected from the group consisting of dwarfism, short stature, hypopituitarism and a disease of low levels of pituitary hormone secretion and to methods for preventive and/or therapeutic treatment of diseases selected from the group consisting of dwarfism, short stature, hypopituitarism and a disease of low levels of pituitary hormone secretion wherein to a subject GPR101 agonist is administered.Type: ApplicationFiled: June 3, 2019Publication date: October 17, 2019Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, UNIVERSITE DE LIEGE, CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGEInventors: Albert Beckers, Adrian Francis Daly, Fabio Rueda Faucz, Constantine A. Stratakis, Giampaolo Trivellin
-
Publication number: 20190290803Abstract: Methods are disclosed for fabricating a three-dimensional engineered blood retinal barrier (BRB) comprising a choroid and retinal pigment epithelial cells. The methods include the use of bioprinting. Also disclosed is a three-dimensional engineered BRB, and its use. Methods are also disclosed for using the three-dimensional engineered BRB, such as for the treatment of retinal degeneration in a subject or screening. A three-dimensional printing insert that is adapted for bioprinting on a culture substrate sheet that is securely retained within and exposed through a printing frame is also disclosed.Type: ApplicationFiled: November 8, 2017Publication date: September 26, 2019Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary Department of Health and Human ServicInventors: Kapil Bharti, Min Jae Song, Russell Louis Quinn